Longevity-focused healthtech startup Biopeak has raised $2.7 million in a follow-on funding round led by NKSquared, the venture capital firm founded by Zerodha co-founder and billionaire investor Nikhil Kamath. The investment marks Kamath’s second bet on the startup, reinforcing his confidence in Biopeak’s approach to preventive and personalised healthcare.
Kamath had earlier invested $1.43 million in Biopeak in August 2024. With this latest infusion, the startup is gearing up to scale operations, expand its clinical footprint, and deepen its technology-driven approach to improving healthspan rather than simply treating illness.
What the Fresh Capital Will Be Used For
Biopeak plans to deploy the new funding across multiple growth initiatives. One of the key priorities is the launch of a new flagship clinic in Bengaluru, which will serve as a central hub for its longevity-focused healthcare services.
Alongside physical expansion, the startup intends to grow its team, particularly in clinical, research, and technology roles. It will also strengthen its network of specialist clinics and diagnostic capabilities to support more comprehensive and data-driven health assessments.
A significant portion of the capital will be invested in enhancing Biopeak’s proprietary AI tools, research infrastructure, and clinical programmes. These investments are aimed at refining personalised health plans and delivering deeper insights into long-term health risks and optimisation strategies.
Why Nikhil Kamath Is Doubling Down
Nikhil Kamath’s second investment signals strong belief in Biopeak’s long-term vision and execution. Through NKSquared, Kamath has increasingly focused on backing startups that operate at the intersection of technology, science, and long-term societal impact.
Longevity and preventive healthcare are emerging as key themes globally, driven by rising lifestyle-related diseases and growing awareness around proactive health management. Biopeak’s model aligns closely with this shift, offering a structured and scientific approach to extending healthy years rather than reacting to illness after it appears.
Kamath’s continued backing gives Biopeak not just capital but also credibility in a competitive and evolving healthtech landscape.
Understanding Biopeak’s Longevity-First Model
Founded by Rishi Pardal and Shiva Subramanian, Biopeak is built around the concept of improving healthspan, the number of years a person lives in good health. Instead of focusing solely on treatment, the startup aims to identify early signals of decline at a cellular and molecular level.
Biopeak combines multiple layers of diagnostics, including cellular and molecular testing, advanced imaging, and AI-driven analysis. These data points are then used to create personalised health plans tailored to an individual’s biology, lifestyle, and long-term goals.
The idea is to move healthcare from a reactive system to a proactive one, where risks are identified early and addressed through targeted interventions.
The Role of AI in Personalised Healthcare
At the core of Biopeak’s platform is its proprietary AI technology. These tools analyse complex diagnostic data to identify patterns that may not be immediately visible through conventional medical assessments.
By integrating AI with clinical expertise, Biopeak aims to deliver insights that help individuals understand how their bodies are ageing and what steps they can take to slow or optimise that process. This includes guidance on nutrition, exercise, recovery, supplementation, and medical interventions where necessary.
The startup believes that AI can play a crucial role in making longevity science more accessible, actionable, and scalable.
Expanding Clinical and Diagnostic Capabilities
Biopeak’s upcoming flagship clinic in Bengaluru is expected to set the standard for its future locations. The clinic will house advanced diagnostic equipment, specialist consultations, and research-backed longevity programmes under one roof.
In addition to flagship centres, Biopeak is strengthening its specialist clinics and diagnostic partnerships. This expansion will allow the company to serve a larger population while maintaining consistency in quality and data collection.
The goal is to create a seamless experience where diagnostics, insights, and interventions are closely integrated.
A Growing Interest in Longevity in India
Longevity-focused healthcare is gaining traction in India, especially among urban professionals who are increasingly aware of lifestyle-related health risks. Rising stress levels, sedentary habits, and early onset of chronic conditions have created demand for preventive and personalised health solutions.
Biopeak is positioning itself at the premium end of this market, targeting individuals who are willing to invest in long-term health optimisation. Its approach reflects a broader shift in healthcare from disease management to performance and longevity enhancement.
As awareness grows, the market for such services is expected to expand significantly.
Founders With a Clear Vision
Rishi Pardal and Shiva Subramanian bring a science-led and systems-driven mindset to Biopeak. Their focus has been on building a platform that combines medical rigour with modern technology, without falling into wellness hype.
By grounding their programmes in diagnostics and measurable outcomes, the founders aim to build long-term trust with patients and clinicians alike.
Their ability to attract repeat investment from a high-profile investor like Nikhil Kamath suggests confidence in both the team and the model.
Building for Scale and Research Depth
Beyond clinics and diagnostics, Biopeak plans to invest heavily in research infrastructure. This includes building datasets that can improve AI models, validate clinical programmes, and support ongoing innovation in longevity science.
Such investments are critical for scaling personalised healthcare while maintaining accuracy and relevance across diverse populations.
The startup’s long-term ambition is to become a leader in longevity science in India, with the potential to expand internationally as the space matures.
Investor Confidence in Preventive Health
The follow-on funding round reflects growing investor interest in preventive and longevity-focused healthcare models. As healthcare costs rise globally, solutions that help people stay healthier for longer are increasingly seen as both impactful and commercially viable.
NKSquared’s continued support positions Biopeak well to attract future partnerships, talent, and capital as it scales.
The Road Ahead for Biopeak
With fresh funding, Biopeak is entering a critical growth phase. The combination of physical expansion, technology investment, and research focus puts the startup in a strong position to deepen its presence in India’s healthtech ecosystem.
If executed well, Biopeak could help redefine how healthcare is delivered, shifting the focus from treating disease to extending healthy, productive years.
Final Thoughts
Biopeak’s $2.7 million follow-on funding from Nikhil Kamath’s NKSquared is a strong endorsement of its longevity-first approach to healthcare. As interest in preventive health and personalised medicine grows, the startup’s blend of diagnostics, AI, and clinical expertise places it at the forefront of a rapidly evolving sector.
With a new flagship clinic, expanded capabilities, and continued investor backing, Biopeak is aiming to build not just a healthcare company, but a long-term health optimisation platform for the future.
